Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930055 · ClinicalTrials.gov registry record
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
A clinical trial, sponsored by Indiana University.
- Terminated
- Registry status
- 2,206
- Enrollment target
NCT04930055 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 2,206 participants.
The verdict
NCT04930055 was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- 2,206 participants
- Enrollment target
Study Summary
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either the Pfizer (BTN162b2), Moderna (mRNA-1273), or the Janssen (Ad26.COV2.S) vaccines.
Interventions
- BIOLOGICAL COVID-19 Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,206 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-03-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930055
The ClinicalTrials.gov registry entry for NCT04930055 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2,206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Vaccination is the first listed.
NCT04930055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04930055 about?
NCT04930055 is a clinical study titled "Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)". The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either th...
What is the current status of trial NCT04930055?
This trial is currently terminated. The enrollment target is 2,206 participants. The study started on 2021-06-30. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT04930055?
The interventions under investigation include: COVID-19 Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT04930055?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.